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Abstract
Rationale Metabotropic glutamate (mGlu) receptors have
been suggested to play a role in neuropsychiatric disorders
including schizophrenia, drug abuse, and depression.
Because serotonergic hallucinogens increase glutamate
release and mGlu receptors modulate the response to
serotonin (5-HT)2A activation, the interactions between
serotonin 5-HT2A receptors and mGlu receptors may prove
to be important for our understanding of these diseases.
Objective We tested the effects of the serotonergic halluci-
nogen and 5-HT2A agonist, 2,5-dimethoxy-4-methylam-
phetamine (DOM), and the selective 5-HT2A antagonist,
M100907, on locomotor activity in the mouse behavioral
pattern monitor (BPM) in mGlu5 wild-type (WT) and
knockout (KO) mice on a C57 background.
Results Both male and female mGlu5 KO mice showed
locomotor hyperactivity and diminished locomotor habitua-
tion compared with their WT counterparts. Similarly, the
mGlu5-negative allosteric modulator 2-methyl-6-(phenyle-
thynyl)pyridine (MPEP) also increased locomotor hyperac-
tivity, which was absent in mGlu5 KO mice. The locomotor
hyperactivity in mGlu5 receptor KO mice was potentiated by
DOM (0.5 mg/kg, subcutaneously (SC)) and attenuated by
M100907 (1.0 mg/kg, SC). M100907 (0.1 mg/kg, SC) also
blocked the hyperactivity induced by MPEP.
Conclusions These studies demonstrated that loss of mGlu5
receptor activity either pharmacologically or through gene
deletion leads to locomotor hyperactivity in mice. Additionally,
the gene deletion of mGlu5 receptors increased the behavioral
response to the 5-HT2A agonist DOM, suggesting that mGlu5
receptors either mitigate the behavioral effects of 5-HT2A
hallucinogens or that mGlu5 KO mice show an increased
sensitivity to 5-HT2A agonists. Taken together, these studies
indicate a functional interaction between mGlu5 and 5-HT2A
receptors.
Keywords Locomotor activity . Metabotropic glutamate
receptors . Mice . Serotonin . 5-HT2A receptors .
Hallucinogen
Metabotropic glutamate (mGlu) receptors are hypothesized
to play a role in neuropsychiatric disorders including
schizophrenia, drug abuse, and depression (Brody et al.
2004; Gupta et al. 2005; Krivoy et al. 2008; Olive 2010).
Metabotropic glutamate receptors are G-protein-coupled
receptors that contribute to the regulation of synaptic
glutamate transmission (Gupta et al. 2005; Kew and Kemp
2005). The mGlu receptors are divided into three main
classes: group I (mGlu1 and mGlu5), group II (mGlu2 and
mGlu3), and group III (mGlu4, 6, 7, and 8). Group I mGlu
receptors are positively coupled to phosphoinositide hydro-
lysis and increase cellular excitability; whereas, groups II
and III mGlu receptors are negatively coupled to adenylate
cyclase resulting in reduced neurotransmitter release (Conn
and Pin 1997; Hubert et al. 2001). While there has been
recent interest in group II mGlu receptors for the treatment
of schizophrenia (Patil et al. 2007), group I mGlu receptors
are of interest as well because of their regional distribution
and their role in synapse formation and neurotransmitter
release (Anwyl 2009; Cauli et al. 2000; Gladding et al.
2009). Due to the putative involvement of mGlu5 receptors
in neuropsychiatric disorders, several groups including ours
A. L. Halberstadt :V. D. Lehmann-Masten :M. A. Geyer :
S. B. Powell (*)
Department of Psychiatry-0804,
University of California San Diego,
9500 Gilman Drive,
La Jolla, CA 92093-0804, USA
e-mail: sbpowell@ucsd.edu
Psychopharmacology (2011) 215:81–92
DOI 10.1007/s00213-010-2115-1
have examined whether mice with a mGlu5 null mutation
display behavioral abnormalities. mGlu5 knockout (KO)
mice show impaired prepulse inhibition of startle (Brody et
al. 2004; Brody and Geyer 2004; Kinney et al. 2003). Data
on the locomotor activity of mGlu5 KO mice have been
mixed. While initial reports found no difference in
locomotor activity (Chiamulera et al. 2001; Lu et al.
1997), more recent studies have reported that mGlu5 KO
mice are hyperactive (Gray et al. 2009). The locomotor
hyperactivity in mGlu5 KO mice is potentiated by the
noncompetitive N-methylD-aspartate (NMDA) antagonist
MK-801 (Gray et al. 2009). From these and other
behavioral experiments (Darrah et al. 2008; Henry et al.
2002; Homayoun et al. 2004; Rosenbrock et al. 2010), it is
clear that mGlu5 receptors modulate NMDA transmission.
In addition to modulating the response to NMDA
antagonists, mGlu receptors also modulate serotonergic
signaling. For example, mGlu2/3 agonists antagonize and
mGlu2/3 antagonists potentiate head shakes induced by the 5-
HT2A/2C receptor agonist 2,5-dimethoxy-4-iodoamphetamine
(DOI) in rats and mice (Gewirtz and Marek 2000; Gonzalez-
Maeso et al. 2008; Klodzinska et al. 2002). Furthermore, the
ability of serotonin (5-HT) and DOI to increase the
frequency of spontaneous excitatory postsynaptic poten-
tials/currents (EPSPs/EPSCs) in layer V pyramidal cells of
PFC is suppressed by activation of mGlu2/3 receptors and
augmented by mGlu2/3 receptor blockade (Benneyworth et
al. 2007; Klodzinska et al. 2002; Marek et al. 2000). Thus,
behavioral and electrophysiological evidence indicates that
mGlu2/3 receptors act to functionally antagonize 5-HT2A
receptor-mediated effects. It was recently suggested that
mGlu2 and 5-HT2A receptors directly form heterocomplexes
in mouse frontal cortex (Gonzalez-Maeso et al. 2008); hence,
a direct interaction between the two receptors may explain
the regulation of 5-HT2A responses by mGlu2.
Despite the current focus on interactions between 5-HT2A
receptors and mGlu2/3 receptors, there is also evidence
indicating that 5-HT2A receptor activity is regulated by
mGlu5 receptors (Marek and Zhang, 2008; Molinaro et al.
2009). For example, activation of mGlu5 receptors with
dihydroxyphenylglycine increases EPSPs in layer V pyra-
midal cells to the same extent as 5-HT2A receptor agonists
(Marek and Zhang 2008). Furthermore, it has been reported
that the mGlu5-negative allosteric modulator 2-methyl-6-
(phenylethynyl)pyridine (MPEP) attenuates the ability of
DOI to increase inositol phospholipid hydrolysis in slices of
mouse frontal cortex (Molinaro et al. 2009). As noted above,
serotonergic hallucinogens increase Glu release and mGlu
receptors modulate the response to 5-HT2A activation. We
have shown that both DOI and MPEP potentiate the effects
of phencyclidine (PCP) on locomotor activity in rats (Henry
et al. 2002; Krebs-Thomson et al. 1998). The interaction
between mGlu5 and 5-HT2A receptors may go beyond a
synergistic effect on Glu release, with mGlu5 receptors
interacting with monoamine transmitters on several levels.
For example, mGlu5 KO mice are insensitive to the
locomotor stimulating and reinforcing effects of cocaine
(Chiamulera et al. 2001). Additionally, MPEP and the
closely related mGlu5-negative allosteric modulator 3-[(2-
methyl-1,3-tiazol-4-yl)ethynyl]-pyridine (MTEP) increase 5-
HT release in the hippocampus and frontal cortex (Smolders
et al. 2008; Stachowicz et al. 2007), and the 5-HT2A/2C
antagonist ritanserin has been shown to block the anxiolytic-
like effects of MTEP in the Vogel conflict-drinking test
(Stachowicz et al. 2007).
We have recently shown that stimulation of 5-HT2A
receptors increases locomotor activity in mice (Halberstadt
et al. 2009), demonstrating that 5-HT2A receptor activation
and genetic deletion of the mGlu5 receptor produce similar
effects on locomotion. Given that finding, and the fact that
interactions occur between 5-HT2A and mGlu5 receptors (as
reviewed above), we have hypothesized that 5-HT2A
receptors are involved in the locomotor hyperactivity
exhibited by mGlu5 receptor KO mice. In the present
investigation, we fully characterized the exploratory
behavior associated with loss of mGlu5 receptor either
through pharmacological blockade or gene deletion. We
also tested the effects of the 5-HT2A agonist 2,5-
dimethoxy-4-methylamphetamine (DOM) and the 5-HT2A
antagonist M100907 on locomotor activity in mGlu5
receptor KO mice.
Materials and methods
Subjects
Mice were housed at a vivarium at the University of
California San Diego (UCSD), an AAALAC-approved
animal facility that meets Federal and State requirements
for care and treatment of laboratory animals. Mice were
housed by genotype in groups of one to four per cage with
access to food and water ad libitum in an animal room on a
reversed light cycle (lights on at 2000 hours, off at
0800 hours). Male C57BL/6J mice were obtained from
Jackson Labs (Bar Harbor, ME) and allowed to acclimate
for approximately 1 week after arrival. Male and female
mGlu5 wild-type (WT) and knockout (KO) mice on a C57
background were bred heterozygously in house at UCSD.
mGlu5 KO mice were generated as previously described
(Chiamulera et al. 2001). The absence of mGlu5 receptors
in mGlu5 KO mice was previously confirmed via immu-
nohistochemistry (Chiamulera et al. 2001). The WT and
mGlu5 KO mice were weaned at 21–24 days of age, at
which point a small portion of the tail (1.5 cm) was
removed for subsequent genotyping by polymerase chain
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reaction (PCR). All experiments were carried out in
accordance with the NIH guide for the care and use of
laboratory animals. All efforts were made to minimize
animal suffering and to reduce the number of animals used.
Apparatus
The mouse BPM system (San Diego Instruments, San
Diego, CA) was used to measure locomotor activity and
investigatory behavior (holepokes, rearing). It consisted of
ten 30.5×61 cm×38 cm Plexiglas chambers with holes in
the floor (three) and walls (three in each long wall and one
in each short wall) each equipped with an infrared photo-
beam for the detection of hole pokes. A 12×24 array of
photobeams 1 cm above the floor was used to define the
animal’s position in an x–y-coordinate system with a
resolution of 1.25 cm. Rearing was detected by an array
of 16 photobeams placed 2.5 cm above the floor and
aligned with the long axis of the chamber. The chamber
was divided into nine virtual zones and transitions were
counted when the animal moved from one zone to another
(Young et al. 2010). Testing occurred in the dark and under
a 65 dB background noise.
Drugs
Drugs used were DOM (National Institute on Drug Abuse
Drug Supply Program, Bethesda, MD); MPEP (Tocris
Bioscience, Ellisville, MO); and (R)-(+)-α-(2,3-dimethox-
yphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
(M100907; Hoechst Marion Roussel Inc., Kansas City,
MO). DOM and MPEP were dissolved in isotonic saline.
M100907 was dissolved in water containing 5% Tween 80.
DOM and MPEP were administered intraperitoneally (IP)
at a volume of 5 ml/kg body weight. M100907 was
administered subcutaneously (SC) at a volume of 5 ml/kg
body weight.
Experimental design
Animals were placed in the mouse BPM chambers
immediately after treatment with DOM, 10 min after
treatment with MPEP, or 30 min after treatment with
M100907. The mice were then tested in the chambers for
60 min (except for experiment 6 where the mice were tested
for 20 min), with data being stored in 10-min blocks. The
experiments involving mGlu5 WT and KO mice used
littermates derived from heterozygous pairings. In experi-
ment 1, the mGlu5 cohort consisted of nine WT and six KO
male mice, and seven WT and eight KO female mice. In
experiment 2, C57BL/6 J mice (n=9–10, 63 total) were
treated with vehicle or 1, 3, 10, or 30 mg/kg MPEP. In
experiment 3, the mGlu5 cohort consisted of five WT and
four KO male mice, and 11 WT and six KO female mice.
The mice were tested in a two-way crossover design with
1 week between tests. Each animal received vehicle as well
as 30 mg/kg MPEP in a semi-randomized, counterbalanced
order, to complete a within-subject design. In experiment 4,
the mGlu5 cohort consisted of seven WT and eight KO
male mice and nine WT and six KO female mice. The mice
were tested in a two-way crossover design with 1 week
between tests. Each animal received vehicle as well as
0.5 mg/kg DOM in a semi-randomized, counterbalanced
order, to complete a within-subject design. In experiment 5,
the mGlu5 cohort consisted of seven WT and eight KO
male mice and nine WT and six KO female mice. The mice
were tested in a two-way crossover design with 1 week
between tests. Each animal received vehicle as well as
1.0 mg/kg M100907 in a semi-randomized, counterbalanced
order, to complete a within-subject design. In experiment 6,
C57BL/6J mice (n=9–11, 40 total) were pretreated with
vehicle or 0.1 mg/kg M100907, and then treated with vehicle
or 20 mg/kg MPEP.
Data analysis
Horizontal locomotor activity was quantified as distance
traveled. Center duration was defined as the amount of time
spent in the center region of the mouse BPM chamber. The
number of rearings was calculated as a measure of
investigatory behavior. Entropy was used to quantify the
predictability of locomotor patterns. This measure quantifies
the predictability of sequences of transitions across different
zones of the BPM chamber (Paulus and Geyer 1993). For
example, a mouse that circles repeatedly along the outer
edges of the arena would move through zones 1, 2, 3, 6, 9,
8, 7, 4, and then back to 1. This pattern results in a low
entropy measure if this sequence of movements is repeated
many times while the animal is in the BPM chamber. In
comparison, an animal that moves through different areas
of the BPM chamber via various routes would generate a
higher level of entropy. Thus, the entropy measure
quantifies the diversity of different routes an animal takes
while in the BPM chamber. Mouse BPM data were
examined in 10-, 20-, 30-, and 60-min time resolutions.
Data were analyzed by using one-, two-, or three-way
analyses of variance (ANOVAs) with sex, genotype, and
drug treatment as between-subject variables, and time as a
repeated measure. Specific post hoc comparisons between
selected groups were done using Dunnett’s many-to-one
test or Tukey’s studentized range method. Significance was
demonstrated by surpassing an α-level of 0.05. In Experi-
ments 3, 4, and 5, sex and genotype were between-subject
variables and drug treatment and time were within-subject
variables. One-way ANOVAs at each time-point were used
for post hoc analysis of these experiments.
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Results
Experiment 1: behavioral effect of mGlu5 gene deletion
Although there was a main effect of sex on distance
traveled (F (1, 26)=6.11; p<0.03), there was no interac-
tion between sex and gene, so data were collapsed across
sex. Figure 1a shows distance traveled, a measure of
locomotor activity, in WT and mGlu5 KO mice. Compared
with WT mice, mGlu5 KO mice displayed greater levels
of locomotor activity in a dark, novel arena (gene effect—
F (1, 28)=29.11; p<0.0001). There was also a significant
interaction between gene and time (F (5, 140)=10.74; p<
0.0001). Post hoc comparisons demonstrated that mGlu5
KO mice were significantly more active than WT mice
during the last 50 min of the test session (p<0.01,
Dunnett’s test). The elevated activity of mGlu5 KO mice
could be due to hyperactivity, or alternatively could be
caused by failure of the animals to habituate to the BPM
chambers during the test session. Therefore, we compared
habituation in the WT and mGlu5 KO mice. Habituation
was assessed as the percent reduction in locomotor
activity from the first to the last 10-min time block. In
WT mice, distance traveled decreased 56% over the
session, from 5,362.0±206.4 cm (mean±SEM) during
the first 10-min block to 2370.6±246.0 cm during the last
10-min block of testing. Conversely, in mGlu5 KO mice,
distance traveled decreased only 19%, from 5,685.0±
304.9 cm during the first 10-min block to 4,588.0±
292.3 cm during the last 10-min block of testing.
Comparison of difference scores demonstrated that mGlu5
KO mice display significantly less habituation than WT
animals (F (1, 28)=21.85; p=0.0001).
Compared to WT mice, the sequences of movements
generated by mGlu5 KO mice had higher entropy
values, indicating that movement sequences were less
repetitive after deletion of the mGlu5 gene (F (1, 28)=
54.58; p<0.001; Fig. 1b). There was an interaction
between sex and time for rearing (F (1, 26)=5.16; p<
0.04), but there was no interaction between sex and gene,
so data were collapsed across sex. As shown in Fig. 1d,
mGlu5 KO mice displayed significantly more rearing
behavior than WT mice (gene effect—F (1, 28)=11.73;
p<0.002) during the first and second 30-min time blocks
(p<0.05, 0.01, Dunnett’s test).
Experiment 2: behavioral effect of MPEP
Treatment of C57BL/6J mice with the selective mGlu5-
negative allosteric modulator MPEP had a significant
effect on distance traveled (F (4, 43)=8.28; p<0.0001),
and there was a significant interaction of treatment and
time (F (20, 215)=2.11; p<0.005). The high dose of
MPEP, 30 mg/kg, was the most effective, increasing
distance traveled throughout the 1-h session (p<0.01,
Dunnett’s test) whereas the increase in locomotor activity
induced by the 10 mg/kg dose reached significance only
during the first 10 min of the session (p<0.05, Dunnett’s
test; Fig. 2a).
There was a significant main effect of MPEP on average
entropy (F (4, 43)=4.75; p<0.003). Post hoc comparisons
demonstrated that 30 mg/kg MPEP significantly increased
entropy during the entire 60-min test session (p<0.01,
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Fig. 1 Behavioral response of mGlu5 receptor WT and KO mice in
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Dunnett’s test; Fig. 2b). MPEP had no effect on rearing at
any of the doses tested.
Experiment 3: effect of mGluR5 gene deletion
on the behavioral response to MPEP
There was not a main effect of sex on distance traveled, nor
was there an interaction between sex and either gene or
drug treatment, or among sex, gene, and treatment, so data
were collapsed across sex (the same was true for all
subsequent experiments involving mGlu5 KO mice). There
was a significant main effect of MPEP treatment on
distance traveled (F (1, 24)=8.17; p<0.009), as well as
interactions between treatment and gene (F (1, 24)=7.95; p
<0.01), and treatment, gene, and time (F (5, 120)=3.44; p<
0.007). Pair-wise comparisons revealed that 30 mg/kg
MPEP significantly increased locomotor activity in WT
mice during the first 50 min of the 1-h test session whereas
MPEP had no effect on locomotor activity in mGlu5 KO
mice (see Fig. 3a). There was also a significant main effect
of gene (F (1, 24)=12.71; p<0.002), and a significant
gene×time interaction (F (5, 120)=7.51; p<0.0001). Post
hoc comparisons demonstrated that mGlu5 KO mice were
significantly more active than WT mice during the last
50 min of the test session.
For entropy, there was a main effect of MPEP treatment
that approached but did not reach significance (F (1, 24)=
4.09; p<0.06), and there was an interaction between
treatment and gene (F (1, 24)=10.90; p=0.003). As
illustrated in Fig. 3b, MPEP significantly increased entropy
in WT mice during the entire 1-h test session whereas
MPEP had no effect on entropy in mGlu5 KO mice. For
rearing, there was a gene effect (F (1, 24)=8.29; p<0.009),
but no effect of treatment with MPEP, and no intertaction of
gene and treatment.
Experiment 4: Effect of mGluR5 gene deletion
on the behavioral response to DOM
There was a significant main effect of treatment with
0.5 mg/kg DOM on distance traveled (F (1, 28)=45.35;
p<0.0001). DOM increased locomotor activity in WT
mice, and this increase was shown by post hoc analyses
to be significant only during the third 10-min block of
testing (F (1, 15)=7.75; p<0.02). Importantly, as shown
in Fig. 4a, DOM markedly increased locomotor activity
in mGlu5 KO mice, leading to a treatment×gene
interaction (F (1, 28)=12.83; p<0.002). Pair-wise com-
parisons demonstrated that DOM increased locomotor
activity in mGlu5 KO mice during all six 10-min blocks
of testing (p<0.02). There was also a significant main
effect of gene on distance traveled (F (1, 28)=7.93; p<
0.009). Pair-wise comparisons revealed that the locomo-
tor activity of vehicle-treated mGlu5 KO mice was
significantly elevated compared with vehicle-treated WT
mice during the last 40-min of testing.
There was a main effect of DOM treatment on
entropy (F (1, 28)=44.95; p<0.0001) and a gene×
treatment interaction (F (1, 28)=25.23; p<0.0001). Post
hoc pair-wise comparisons revealed that 0.5 mg/kg DOM
had no effect on entropy in WT mice but significantly
increased entropy in mGlu5 KO mice during the first
30 min of testing (F (1, 13)=33.09; p=0.0001; Fig. 4b).
As expected, vehicle-treated mGlu5 KO mice displayed
greater entropy values than vehicle-treated WT mice (F (1,
28)=22.24; p=0.0001). As with distance traveled and
entropy, we also found evidence that the effect of DOM to
reduce rearing behavior was enhanced in mGlu5 KO mice.
There was a significant main effect of treatment with
0.5 mg/kg DOM on rearing (F (1, 28)=4.44; p<0.05), and
an interaction between treatment and time (F (1, 28)=
5.25; p<0.03). Importantly, there was a significant three-
way interaction between treatment, gene, and time (F (1,
28)=9.07; p<0.006). Specific pair-wise comparisons
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revealed that 0.5 mg/kg DOM produced only a small
non-significant decrease in rearing in WT mice whereas
in mGlu5 KO mice the drug significantly decreased
rearing during the first 30 min of testing (F (1, 13)=
12.58; p<0.004; Fig. 4c). This experiment also confirmed
that mGlu5 KO mice display significantly more rearing
than WT mice after treatment with vehicle (F (1, 28)=
4.49; p<0.05).
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Experiment 5: reversal of the behavioral effects of mGlu5
gene deletion by M100907
As expected, vehicle-treated mGlu5 KO mice displayed
increased levels of locomotor activity compared with WT
mice, leading to an interaction between gene and time (F (5,
140)=9.37; p<0.0001). Post hoc comparisons confirmed
that mGlu5 KO mice were significantly more active than
WT animals during the last 50 min of the test session.
Importantly, as shown in Fig. 5a, the locomotor hyperactivity
exhibited by mGlu5 KO mice was significantly attenuated
by treatment with 1.0 mg/kg M100907 (treatment×gene—F
(1, 28)=15.12; p<0.0006). Post hoc analyses indicated that
after treatment with M100907 the mGlu5 KO mice were
only hyperactive during the last 10-min of testing.
Treatment with M100907 significantly decreased loco-
motor activity in WT and KO mice (treatment effect—F
(1, 28)=66.76; p<0.0001).
As we found in our previous experiments, for vehicle-
treated animals the average entropy values were greater in
mGlu5 KO mice than in WT mice (gene effect—F (1, 28)=
7.09; p<0.02). There was also a two-way interaction
between treatment and gene (F (1, 28)=17.60; p=0.0002),
and a three-way interaction between treatment, gene, and
time (F (1, 28)=4.72; p<0.04). Subsequent pair-wise
comparisons confirmed that vehicle-treated mGlu5 KO mice
displayed elevated average entropy values relative to
vehicle-treated WT mice, and further demonstrated that after
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treatment with M100907 there was no appreciable difference
between entropy values for mGlu5 KO mice and WT mice
(see Fig. 5b). M100907 itself produced a decrease in average
entropy values (F (1, 28)=50.33; p<0.0001). Vehicle-treated
mGlu5 KO mice displayed significantly increased levels of
rearing compared with WT mice (gene effect—F (1, 28)=
4.88; p<0.04). The increase in rearing displayed by mGlu5
KO mice was significantly attenuated by administration of
1.0 mg/kg M100907, leading to an interaction between
treatment and gene (F (1, 28)=7.27; p<0.02). As illustrated
in Fig. 5c, post hoc comparisons confirmed that whereas
vehicle-treated mGlu5 KO mice displayed significantly more
rearing than WT mice during the first (F (1, 28)=6.69; p<
0.02) and second (F (1, 28)=6.79; p<0.02) halves of the test
session, after treatment with M100907 there was no
significant difference between the amount of rearing behavior
displayed by WT and mGlu5 KO mice. Treatment with
M100907 significantly decreased rearing behavior (treatment
effect—F (1, 28)=38.02; p<0.0001).
Experiment 6: blockade of the behavioral effect of MPEP
by M100907
To determine whether the 5-HT2A receptor is involved in
mediating the effects of MPEP in the BPM, we tested the
effect of an intermediate dose of MPEP (20 mg/kg) in
animals pretreated with M100907. Due to the fact that the
effects of MPEP at doses <30 mg/kg are transient (see
Fig. 2a), for this experiment the animals were only tested in
the BPM for 20 min. MPEP significantly increased
locomotor activity (F (1, 36)=4.68; p<0.04), and pretreat-
ment with 0.1 mg/kg M100907 blocked the effect of MPEP,
leading to an interaction that approached but did not reach
significance (F (1, 36)=3.93; p=0.0552). Importantly, post
hoc analysis confirmed that pretreatment with M100907
completely blocked the ability of MPEP to increase
locomotor activity (p<0.01, Tukey’s test; see Fig. 6). There
was a main effect of pretreatment with M100907 (F (1, 36)=
8.26; p<0.007), but pair-wise comparisons demonstrated that
M100907 pretreatment did not significantly reduce locomo-
tor activity in vehicle-treated animals (Fig. 6). MPEP had no
effect on average entropy or the number of rearings.
Discussion
In recent years, there has been increasing recognition of an
interaction between serotonergic and metabotropic gluta-
mate signaling, particularly between 5-HT2A receptors and
mGlu2/3 receptors (Benneyworth et al. 2007; Klodzinska et
al. 2002; Marek et al. 2000; Gewirtz and Marek 2000;
Klodzinska et al. 2002). Evidence has also recently
emerged indicating that 5-HT2A receptor function may be
regulated by mGlu5 receptors (Marek and Zhang 2008;
Molinaro et al. 2009). Accordingly, the current studies were
designed to examine the behavioral effects induced by
alteration of mGlu5 signaling, and to assess the behavioral
interaction between 5-HT2A receptors and mGlu5 receptors.
Confirming a previous report in DBA/2J mice (McGeehan
et al. 2004), we found that MPEP produced hyperactivity in
C57BL/6J mice. Another noncompetitive mGlu5 antagonist,
fenobam, has also been reported to increase locomotor
activity in Swiss–Webster mice (Montana et al. 2009).
Importantly, MPEP had no effect on locomotor activity in
mGlu5 KO mice, demonstrating that this effect of MPEP is
mediated specifically by mGlu5 receptors. Both 10 and
30 mg/kg MPEP induced hyperactivity, but the effects of
10 mg/kg were transient compared with those induced by
30 mg/kg, which persisted throughout the 60-min test
session (see Fig. 2a). Interestingly, administration of
10 mg/kg MPEP to C57BL/6J mice results in full occupancy
of forebrain mGlu5 receptors within 5 min, but brain levels
rapidly decline thereafter, with occupancy decreasing to
∼75% and ∼50% at 30- and 60-min post-administration,
respectively (Anderson et al. 2003). The fact that MPEP
produces only transient behavioral effects unless adminis-
tered at doses >10 mg/kg indicates that very high levels of
mGlu5 receptor occupancy are required for MPEP to
produce sustained effects on locomotor activity.
In addition to testing the effect of the selective mGlu5-
negative allosteric modulator MPEP on locomotor activity,
we also assessed activity in mGlu5 KO mice. Compared with
WT littermates, mGlu5 KO mice were hyperactive and failed
to habituate to the BPM chambers. Another group (Gray et al.
2009) has also reported that mGlu5 KO mice display a
hyperactive behavioral phenotype, but those workers
failed to detect differences in rates of habituation
between WT and mGlu5 KO mice (although see
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(Chiamulera et al. 2001). In the present investigation,
habituation was assessed over 60 min whereas Gray et al
(2009) assessed habituation over 30 min, suggesting that
the duration of testing in the previous investigation was
insufficient to detect differences in habituation between
WT and KO animals.
Experiments in rats have shown that three independent
factors characterize unconditioned motor activity: amount
of activity (including the amount of locomotor activity);
exploratory behavior (including rearing); and behavioral
organization (including entropy) (Paulus and Geyer 1993).
Although we have not validated this three-factor model for
mice, the fact that we detected alterations of locomotor
activity, rearing, and entropy in the mGlu5 KO mice
indicates that all three factors controlling spontaneous
activity are altered in the mice. This observation indicates
that loss of the mGlu5 gene has profound effects upon all
three aspects of unconditioned motor behavior.
The behavioral effects induced by deletion of the gene
for the mGlu5 receptor, including increases in locomotor
activity, entropy, and rearing behavior, were reversed by
administration of the highly selective 5-HT2A receptor
antagonist M100907. This finding indicates that activation
of 5-HT2A receptors is responsible for the behavioral
abnormalities exhibited by mGlu5 receptor KO mice.
Indeed, we recently reported that 5-HT2A receptor activa-
tion produces increases in locomotor activity in mice
(Halberstadt et al. 2009). Blockade of mGlu5 receptors
with MTEP has been shown to increase 5-HT release and to
induce behavioral effects that are reversed by a 5-HT2A
antagonist (Stachowicz et al. 2007). Likewise, we found
that the ability of MPEP to induce locomotor hyperactivity
was blocked by pretreatment with M100907. Therefore,
one potential explanation for the locomotor hyperactivity
displayed by mGlu5 KO mice is that the loss of mGlu5
signaling results in increased 5-HT release, leading to
activation of the 5-HT2A receptor.
It is important to note that although M100907 is highly
selective for the 5-HT2A receptor, it does have modest
affinity for 5-HT2C and α1-adrenergic receptors (Kehne et
al. 1996). The dose of M100907 that was used to reverse
the behavioral phenotype of mGlu5 KO mice (1.0 mg/kg,
SC) is relatively high compared with doses that are
typically used to block 5-HT2A receptor-induced behaviors
in mice (Kehne et al. 1996; Benneyworth et al. 2005;
Fantegrossi et al. 2006; Winter et al. 2005), and thus it is
possible that interactions of M100907 with 5-HT2C or α1-
adrenergic receptors may have played a role in the blockade
of the mGlu5 KO phenotype. Three factors, however,
indicate that the effect of M100907 is likely mediated by 5-
HT2A receptor antagonism. Firstly, M100907 produces
negligible occupation of central α1-adrenergic receptors in
mice at 1.0 mg/kg SC (Patel et al. 2001) and doses as high
as 16 mg/kg fail to block lethality induced by the α1
agonist phenylephrine (Kehne et al. 1996). Secondly, the
behavioral effects induced by M100907 at 1.0 mg/kg are
distinct from those produced by the 5-HT2C receptor-
selective antagonist SB242,084 (Fletcher et al. 2007), and
are similar to, although more pronounced than, the effects
produced by lower doses of M100907. This finding
indicates that M100907 likely retains selectivity for the 5-
HT2A receptor versus the 5-HT2C receptor when adminis-
tered to mice at 1.0 mg/kg SC. Finally, a 10-fold lower dose
of M100907 (0.1 mg/kg) completely blocked the increase
in activity induced by the mGlu5 allosteric antagonist
MPEP. This finding confirms that a low, 5-HT2A-selective
dose of M100907 is capable of blocking the behavioral
effect induced by the loss of mGlu5 receptor signaling.
We have shown previously that DOI increases locomotor
activity and reduces rearing behavior, effects that are absent
in 5-HT2A KO mice and are therefore likely mediated by
activation of 5-HT2A receptors (Halberstadt et al. 2009).
The present investigation demonstrates that the effects of a
low dose (0.5 mg/kg) of the DOI analog and 5-HT2A/2C
agonist DOM on locomotor activity and investigatory
behavior are markedly potentiated in mGlu5 KO mice. It
is difficult to reconcile this finding with the hypothesis that
the locomotor hyperactivity exhibited by mGlu5 KO mice
is a consequence of elevated release of 5-HT. An alternative
explanation for the finding with DOM is that mGlu5 KO
animals display supersensitive responses to 5-HT2A recep-
tor activation. Indeed, the fact that the behavioral pheno-
type exhibited by mGlu5 receptor KO mice is reversed by
M100907 could also be taken as evidence that the
hyperactivity observed in those animals is a consequence
of enhanced sensitivity to 5-HT2A receptor activation,
induced either by endogenous 5-HT or by the constitutive
activity of the receptor. As yet, no evidence has emerged
that mGlu5 KO mice display abnormalities of 5-HT2A
receptor expression or signaling. However, there is evi-
dence that the mGlu5 receptor acts to regulate the response
to 5-HT2A receptor activation. It was recently reported that
the ability of DOI to stimulate inositol phospholipid
hydrolysis in slices of mouse frontal cortex is attenuated
by MPEP (Molinaro et al. 2009). 5-HT2A agonists increase
Glu release in the neocortex of rats (Muschamp et al. 2004;
Scruggs et al. 2003), and the findings reported by Molinaro
may reflect the fact that mGlu5 receptors are tonically
activated by Glu released in response to 5-HT2A receptor
stimulation. Based on the present data, it appears that the
mGlu5 receptor regulates the behavioral response to 5-HT2A
receptor activation. Thus, mGlu5 normally acts to attenuate
5-HT2A receptor-induced hyperactivity, and in the absence of
mGlu5 signaling (as a consequence of administration of
MPEP or by genetic deletion of the receptor) the behavioral
influence of the 5-HT2A receptor is markedly augmented.
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Several reports demonstrate that MPEP potentiates the
ability of the noncompetitive NMDA receptor antagonists
MK-801 and PCP to induce hyperlocomotion (Henry et al,
2002; Homayoun et al. 2004). Microdialysis studies have
demonstrated that NMDA antagonists increase Glu outflow
(Adams and Moghaddam 1998; Moghaddam et al. 1997).
Based on the fact that NMDA receptor antagonists such as
PCP and 5-HT2A agonists such as DOM increase Glu
release, it has been suggested that the glutamatergic system
may represent a common final pathway for their behavioral
effects (Quednow et al. 2009). The fact that mGlu5 receptor
blockade potentiates the locomotor effects of both PCP and
DOM raises the possibility that the mGlu5 receptor
normally acts to attenuate hyperlocomotion induced by
increases in Glu release, and in the absence of mGlu5
signaling the locomotor effects of Glu-releasing agents are
greatly potentiated.
The identity of the brain regions(s) responsible for the
behavioral effects observed in the present experiments is
unclear. mGlu5 receptors (Romano et al. 1995) and 5-HT2A
receptors (Cornea-Hebert et al. 1999; Miner et al. 2003) are
heavily expressed in rat prefrontal cortex. However, it is
unlikely that the prefrontal cortex is a substrate for these
behavioral effects because activation of 5-HT2A receptors
and mGlu5 receptors has been shown to increase Glu
release onto layer V pyramidal cells located in that brain
region (Aghajanian and Marek 1997; Marek and Zhang
2008). Furthermore, it does not appear that the ability of 5-
HT to induce EPSCs in prefrontal cortical neurons is
significantly augmented in the presence of MPEP. Based on
the fact that mGlu5 KO mice display facilitated responses
to DOM, it might be expected that MPEP would potentiate
the electrophysiological response to 5-HT. Other possible
substrates for the locomotor effects of mGlu5 blockade and
the interaction between mGlu5 receptors and 5-HT2A
receptors include the terminal fields of the mesolimbic
and mesostriatal dopaminergic projections. Importantly,
mGlu5 receptors (Romano et al. 1995; Shigemoto et al.
1993; Testa et al. 1994) and 5-HT2A receptors (Cornea-
Hebert et al. 1999; Morilak et al. 1993) are coexpressed in
nucleus accumbens and dorsal striatum, areas where
conventional psychostimulant drugs are known to act.
Indeed, mGlu5 KO mice are insensitive to the locomotor
stimulating and reinforcing effects of cocaine (Chiamulera
et al. 2001), suggesting that mGlu5 receptors do interact
with dopamine presumably in these striatal areas.
The current set of studies demonstrated that loss of
mGlu5 receptor activity either pharmacologically or
through gene deletion leads to locomotor hyperactivity in
mice. Additionally, the gene deletion of mGlu5 receptors
increased the behavioral response to the 5-HT2A agonist
DOM, suggesting that mGlu5 receptors either mitigate the
behavioral effects of 5-HT2A hallucinogens or that mGlu5
KO mice show an increased sensitivity to 5-HT2A agonists.
Taken together these studies indicate that similar to the
functional interaction between mGlu2/3 receptors and 5-
HT2A hallucinogens, there also exists a functional interac-
tion between mGlu5 and 5-HT2A receptors. This interaction
may be important to our basic understanding of the
neurochemical and behavioral effects of hallucinogens and
potentially to the pathophysiology and treatment
approaches for neuropsychiatric disorders such as schizo-
phrenia (i.e., positive allosteric modulators of mGlu5
(Marek et al. 2010; Pietraszek et al. 2007).
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